Designing peptide vaccines for cellular cross-presentation.
Synthetic peptides are safe and relatively cheap vaccine components. However, the efficiency of peptide vaccines is limited by peptide interaction with non-professional antigen-presenting cells, which may hamper induction of productive T-cell responses. This paper argues that peptide vaccines should be modified for exclusive uptake by cells with the capacity to prime T-cell responses. Moreover, design of peptide vaccines should take intracellular antigen processing into account and exploit cellular mechanisms of proteolysis, transport and HLA class I assembly of antigenic peptides to enhance efficiency of T-cell priming and stimulation.
van Endert
P M
PM
Institut National de la Santé et de la Recherche Médicale Unite 25, 161 rue de Sèvres, 75015 Paris, France.
D015395:Histocompatibility Antigens Class I / Q000276:immunology; D010455:Peptides / Q000276:immunology*; D014612:Vaccines / Q000276:immunology*
D015395:Histocompatibility Antigens Class I; D010455:Peptides; D014612:Vaccines